Question 1

Is there a recommended amount and injection frequency for peptides?

Accepted Answer

No, and the reason is worth more than the answer. A 2026 primer written for orthopaedic and sports medicine physicians reviewed BPC-157 (body protection compound 157), thymosin beta-4, TB-500, CJC-1295 with ipamorelin, tesamorelin and GHK-Cu (copper tripeptide-1), and concluded that information regarding the indications, dosing, frequency, and duration of treatment remains unknown. A 2026 review of peptides in gerontology arrived at the same place from a different direction, listing as open questions that significant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy. Two sets of authors asking different things found the same hole. What that does not mean is that nothing has been measured. A great deal has been measured, in rodents and in patients carrying a diagnosis, and the rest of this page is what those measurements actually were. What it means is that none of it has been turned into a schedule for a healthy adult, which is a different thing from a schedule existing somewhere and being hard to find.

Question 2

How much peptide goes into a daily injection?

Accepted Answer

Three figures in the published record are daily, and every one of them carries its population with it. In a trial of 412 people with HIV and abdominal fat accumulation, participants received a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks. In a tanning study in seven volunteers, melanotan-I was administered at a dose of 0.16 mg/kg/day (Monday-Friday), over a two week period. In prepubertal children with growth hormone deficiency, limited data indicated that once daily subcutaneous sermorelin 30 microg/kg bodyweight given at bedtime raised height velocity over twelve months. Read the three together and the pattern is the point. A fixed milligram figure, a per-kilogram figure and a weekday-only schedule, in three populations, for three unrelated purposes. Nothing in that set is a daily amount for peptides as a category. It is three answers to three questions, and none of the three questions was about a healthy adult.

Question 3

Why are most of the published amounts written per kilogram, in animals?

Accepted Answer

Because that is how animal work is done. An amount in a rodent experiment is set against the weight of the animal, so it is written as a rate — micrograms or milligrams per kilogram — rather than as a quantity in a vial. A 2026 scoping review of six widely sold compounds found that overall, 67% of identified publications utilized preclinical animal models. The individual figures look like this. In obese Zucker rats, daily treatment with an oral dose of AOD9604 of 500 microg/kg body weight for 19 days was compared against untreated controls. In a 2026 tendon experiment, thirty-two Sprague-Dawley rats were randomly assigned to four groups, with eight rats in each group: control, BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day), and combined BPC-157 + TB-500, delivered intraperitoneally — into the abdominal cavity, which is not a route people use. In an Alzheimer's model, transgenic mice were given 15 mg/kg GHK-Cu intranasally 3 times per week for 3 months. A reader weighing eighty kilograms can multiply any of those figures and get a number out. The number is arithmetic rather than evidence, because the animal-to-human step it quietly skips is the one step none of this research takes.

Question 4

Why is a figure from a study not a protocol?

Accepted Answer

Because a study amount is an input, not a finding. A team picks it to answer one question — does this move a marker, at this exposure, in this model — and the experiment is built around holding everything else still. Lift the figure out of that setting and you leave behind the species, the body weight, the condition under study, the monitoring and the rules for stopping, all of which came attached. A 2026 critical review of peptide use in sport made the mismatch explicit: most published studies examine therapeutic applications under controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding. The same scoping review that counted the animal work also recorded that significant heterogeneity existed in dosing and route of administration, which is what a field without a settled amount looks like from the inside. So the figure is real and the protocol is not. That distinction governs this whole page, and it is why every number below is attributed to the experiment it came out of rather than offered as somewhere to begin.

Question 5

Which compounds have an amount a regulator has approved?

Accepted Answer

A handful, and for those the figure is a regulatory fact rather than an opinion of ours. In weight management, liraglutide 3.0 mg daily, the first GLP-1 RA approved for treatment of overweight, set the pattern, and semaglutide followed at 2.4 mg once weekly. Tirzepatide is approved at the same doses (5, 10 and 15 mg) for both type 2 diabetes (T2D) and chronic weight management. Tesamorelin carries a much narrower approval, and its label is specific: the dosage is 2 mg (two 1 mg vials) injected subcutaneously once a day, for excess abdominal fat in adults with HIV-associated lipodystrophy — a redistribution of body fat seen on long-running HIV therapy. Bremelanotide is governed by a ceiling rather than a schedule, since prescribing guidelines recommend no more than 1 dose in 24 hours and no more than 8 doses per month. Each of those was reviewed by a regulator and printed on a label. Reporting one is the same class of act as reporting that a compound carries no approval at all, and it reaches exactly as far as the labelled product it belongs to.

Question 6

Does an approved schedule apply to a compounded or research-grade vial?

Accepted Answer

No, and this is the single most load-bearing sentence on the page. An approved schedule belongs to the thing that was approved: a known molecule at a verified strength, assayed, labelled and traceable to a lot number. A compounded or grey-market vial of the same molecule has none of that standing behind it, so the labelled figure says nothing about what is actually in the glass. The federal recall record supplies the demonstration. One entry reads Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy Subpotent Drug, which is a regulator recording that the strength on the label was not the strength in the liquid. Another lists Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, at a concentration no approved pen is sold in. European laboratories testing seized injectables put the general case plainly: the falsified biopharmaceuticals are a health risk because they lack all labelling and may contain unlicensed drugs for injection. A schedule is only ever as good as the strength it is calculated against. Where the strength is unverified, the arithmetic built on it is unverified too, whatever the carton says.

Question 7

How often were these compounds given?

Accepted Answer

Frequency in the published work follows the molecule, not a rule about peptides. Semaglutide has a long t1/2 — its half-life — that allows for once-weekly subcutaneous administration, which is why the trials dosed it weekly rather than daily. Growth hormone ran the other way and was then re-made to match. Lonapegsomatropin is administered as a once-weekly subcutaneous injection, and the whole point of that form was to take the place of a daily shot. Bremelanotide is a subcutaneous injection that can be administered as needed approximately 45 minutes prior to sexual activity, which is not a schedule at all. Weekly, daily and on demand all sit in the same record. Each one was settled by how long the molecule lasts in the body and by what it was being asked to do. A frequency carried over from one compound to the next is a guess in the clothes of a protocol.

Question 8

How long did the published courses run?

Accepted Answer

From a fortnight to a year, with each length chosen to suit the question being asked. In the rat tendon work, treatments were administered intraperitoneally for four weeks postoperatively, which is roughly how long early tendon repair takes in a rat. The melanotan-I tanning study ran ten daily injections across two weeks, because that is the timescale on which tanning can be measured. The longest continuous stretch among the research behind this page belongs to tesamorelin, where patients were randomized to tesamorelin 2 mg (n = 273) or placebo (n = 137) s.c. daily for 26 weeks and then re-randomised for a further 26. That same trial also reported the thing a question about duration is usually really asking. Though effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment, where VAT is visceral fat, the deep abdominal fat the trial was measuring. A course length is not a cycle and it is not a recommendation. It is how long the measuring went on for.

Question 9

Is there a cycle length, or a break, in the published work?

Accepted Answer

Cycling — a set run of weeks on, then a set run off — is a structure the published work does not use. The trials among the research behind this page either ran to an endpoint or simply stopped. Several then opened extensions that carried straight on, with no break built into them: one open-label extension trial evaluated the long-term safety and efficacy of once-weekly lonapegsomatropin in children. Where the question is raised at all, it is raised as unresolved. A 2006 review of somatropin in HIV-associated wasting listed among its open questions the management of patients after 12 weeks' therapy, and whether maintenance strategies might exist. That is a cycling question, asked by doctors, about an approved product, and still open two decades later. The eight-weeks-on, four-weeks-off tables that circulate online are not drawn from any of this, because there is nothing in it to draw them from.

Question 10

Where and how were the injections given?

Accepted Answer

Under the skin, in most of the human work, and the published descriptions are about method rather than location. In the bremelanotide phase 3 programme, patients self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector, which is a device choice rather than a choice of spot. Other routes turn up wherever the molecule needed them: in rat behavioural work, Semax was injected intranasally in doses of 50 and 500 microg/kg, because the nose was the route under test, and the AOD-9604 rodent work went through the mouth instead. None of the records among these sources sets one injection site against another for the same compound, so a claim that one spot outperforms another has not come from this literature. What the route genuinely does change is how much of the compound reaches the bloodstream, which is why a figure taken from an intranasal study and a figure taken from an injected study are not interchangeable even when the molecule is identical.

Question 11

What does reconstitution actually work out?

Accepted Answer

Reconstitution is arithmetic, and it is a different question from how much to give. A lyophilised vial holds a dry mass; adding a measured volume of liquid converts that mass into a concentration, and the concentration is the thing a syringe can actually measure. One federal record describes Tesamorelin, 1mg/vial, 6mL vial, Lyophilized Powder for Reconstitution and Subcutaneous Injection — one milligram of solid, six millilitres of room, and a resulting strength that depends entirely on how much liquid goes in. The same compound can also be written two ways. One recall lists BPC-157, 2000 MCG/ML, 5 ML vial while another lists BPC-157 2 mg/mL (5 mL) Injection, 5 mL vials, and those are one concentration recorded in two units. Working millilitres out from a vial strength and a target amount is mechanical, and the calculator at the reconstitution calculator will do it on figures you supply. What no calculator can supply is the target amount itself, because that is precisely the thing this literature does not establish.

Question 12

How do mg, mcg, mL and IU line up?

Accepted Answer

Four units appear on vials and syringes, and only two of them convert into each other by arithmetic alone. A milligram is a thousand micrograms, so 2 mg and 2000 mcg are a single quantity written twice over. Millilitres measure liquid rather than substance, so a volume figure means nothing at all until the concentration is known. International units are the awkward case, because an IU is defined separately for each substance against a reference standard, which leaves no general conversion to apply. Growth hormone has one, and a label states it: a federal record lists TEV-TROPIN [somatropin (rDNA origin) for injection] 5 mg (15 IU) 1-count bottle, which pins that one compound at three international units per milligram and says nothing whatever about any other. Labels also contradict themselves. One recall entry reads Melanotan I 200mcg/mL (2mg/ml), a) 1.5mL-vial, b) 5 mL-vial, where the two strengths given for the same liquid differ by a factor of ten. Conversions are at the dosage converter, and syringe markings are worked through at the syringe unit converter.

Question 13

How many injections are in a 10 mg vial?

Accepted Answer

That turns on one number the vial itself does not carry, which is the amount per injection. The division is trivial once you have it: total milligrams divided by milligrams per injection, and nothing else enters into the calculation. What the records do show is how widely the strengths run. One compounded entry reads Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, and another lists Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, which is an eight-fold spread in concentration across two vials of comparable size. So a figure like ten milligrams describes what is in the glass and not how long the glass will last. Anybody asking how long a vial lasts is really asking what goes into each injection, and that question routes back to the particular compound: the amounts recorded for growth hormone are gathered at the HGH dosage page, and the tirzepatide label figures at the Tirzepatide dosage page.

Question 14

Where do the dosing charts and protocols online come from?

Accepted Answer

Rarely from the places they are credited to. A 2026 review built expressly to set the two bodies of writing side by side worked by stratifying peptides into evidence tiers from regulatory-grade randomized trial data to a complete absence of human studies, and compared that range against commonly encountered online self-administration protocols. A chart that hands every compound a tidy weekly figure has flattened that entire range down to nothing. The traffic driving those charts is real and is itself unmeasured: a 2026 critical review recorded that anecdotal reports and widespread promotion on social media suggest growing uptake among recreational gym-goers, including younger individuals, but prevalence studies are lacking. One thing this site will not do is attach an amount to a named person. We are asked constantly what a particular actor or podcaster injects, and we do not answer, because a private individual's medical care is not ours to report and a rumoured protocol is not evidence of anything at all. The pattern is worth naming. The person is not.

Question 15

Why don't the published figures agree with each other?

Accepted Answer

Three reasons, and none of them is that one figure is the correct one. The first is that the experiments were asking unrelated questions in unrelated species, so the amounts were never going to line up. The second is scale: a 2025 review of injectable peptides recorded that there is scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides in tendon, muscle, and cartilage injury, and a thin literature produces scattered numbers instead of a convergent one. The third is that some compounds have no published amount to vary from in the first place. A 2026 orthopaedic review writes that neuroactive peptides like selank, semax, and dihexa enhance brain-derived neurotrophic factor and HGF/c-Met pathways critical to neuroplasticity, naming a compound for the pathway it acts on while reporting no quantity for it anywhere, and concluding that there is a current lack of clinical trials. So a reader hunting for a dihexa figure is not searching badly. The figure is one of the things this body of work has not produced, and a chart that supplies one has supplied it from somewhere else entirely.

Peptide Dosing